HC Wainwright Estimates CG Oncology FY2030 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Research analysts at HC Wainwright issued their FY2030 EPS estimates for shares of CG Oncology in a research report issued on Monday, January 26th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of $4.42 for the year. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share.

Other equities analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research note on Wednesday, January 21st. Wall Street Zen upgraded shares of CG Oncology from a “sell” rating to a “hold” rating in a report on Friday, October 3rd. Piper Sandler raised their price target on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a research report on Friday, January 16th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $82.00 price objective on shares of CG Oncology in a research report on Monday, January 12th. Finally, Morgan Stanley set a $93.00 price objective on shares of CG Oncology in a research note on Friday, January 9th. Eleven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $67.83.

CG Oncology Stock Down 0.8%

Shares of NASDAQ:CGON opened at $53.42 on Wednesday. The business’s 50 day moving average is $45.37 and its 200 day moving average is $38.00. CG Oncology has a 12-month low of $14.80 and a 12-month high of $57.88. The stock has a market cap of $4.31 billion, a price-to-earnings ratio of -26.19 and a beta of 1.35.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.57) EPS for the quarter, hitting analysts’ consensus estimates of ($0.57). The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.07 million.

Hedge Funds Weigh In On CG Oncology

A number of large investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in shares of CG Oncology by 190.3% during the 3rd quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock valued at $222,055,000 after purchasing an additional 3,613,885 shares during the period. Bank of America Corp DE boosted its stake in CG Oncology by 409.9% in the 2nd quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock worth $45,156,000 after purchasing an additional 1,396,170 shares during the period. Candriam S.C.A. purchased a new position in CG Oncology during the 2nd quarter valued at about $19,854,000. Vanguard Group Inc. increased its position in shares of CG Oncology by 11.4% during the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock valued at $264,933,000 after buying an additional 670,770 shares during the period. Finally, Millennium Management LLC increased its position in shares of CG Oncology by 139.4% during the first quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock valued at $14,597,000 after buying an additional 347,055 shares during the period. 26.56% of the stock is owned by institutional investors.

Insider Buying and Selling at CG Oncology

In other news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $41.43, for a total transaction of $41,430.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director James Mulay sold 11,145 shares of CG Oncology stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $52.47, for a total value of $584,778.15. The SEC filing for this sale provides additional information. Insiders own 7.40% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.